• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Business Development Director Christianson Mark sold $5,596 worth of shares (8,981 units at $0.62), decreasing direct ownership by 3% to 271,491 units (SEC Form 4)

    5/23/25 4:03:34 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care
    Get the next $NMTC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Christianson Mark

    (Last) (First) (Middle)
    7599 ANAGRAM DR.

    (Street)
    EDEN PRAIRIE MN 55344

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Business Development Director
    3. Date of Earliest Transaction (Month/Day/Year)
    05/21/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/21/2025 S 14 D $0.65 280,458 D
    Common Stock 05/22/2025 S 8,967 D $0.623 271,491 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Stephanie Swan, by Power of Attorney 05/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NMTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NMTC

    DatePrice TargetRatingAnalyst
    5/5/2025$1.45Buy
    Ladenburg Thalmann
    3/29/2022$6.00 → $2.00Buy → Hold
    Craig Hallum
    12/3/2021$5.75Buy
    Alliance Global Partners
    11/15/2021$6.00Buy
    Craig-Hallum
    More analyst ratings

    $NMTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025

      EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025. Dave Rosa, President and CEO of NeuroOne will be meeting with investors during the two-day event that will feature informative panel discussions, keynote talks and corporate presentations on medical devices, imaging technologies, diagnostics, AI/data analytics and digital

      5/29/25 1:05:36 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

      Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025. Recent Company Highlights Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablati

      5/13/25 7:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

      Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company's Scientific Advisory Board since 2018. Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years' experience serving patients and advancing innovative therapies to alleviate neurol

      5/12/25 8:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by NeuroOne Medical Technologies Corporation

      SCHEDULE 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      5/15/25 3:49:33 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

      5/13/25 8:15:21 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by NeuroOne Medical Technologies Corporation

      10-Q - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

      5/13/25 8:01:14 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Numerical Tech with a new price target

      Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45

      5/5/25 8:32:14 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Numerical Tech downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Numerical Tech from Buy to Hold and set a new price target of $2.00 from $6.00 previously

      3/29/22 8:37:16 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners initiated coverage on NeuroOne Medical Tech with a new price target

      Alliance Global Partners initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $5.75

      12/3/21 9:56:11 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

      SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      11/26/24 8:42:10 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

      SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      11/14/24 3:41:01 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by NeuroOne Medical Technologies Corporation

      SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      2/14/24 4:51:41 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Leadership Updates

    Live Leadership Updates

    See more
    • NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

      Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company's Scientific Advisory Board since 2018. Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years' experience serving patients and advancing innovative therapies to alleviate neurol

      5/12/25 8:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. Mr. Volker held the role of Vice President and General Manager of International at

      11/14/23 5:15:00 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne Appoints Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs

      EDEN PRAIRIE, Minn., Jan. 18, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces the appointment of Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs. Mr. Wilhelmy joins NeuroOne from HLT Medical, a subsidiary of the Bracco Group, where he was the Vice President Quality Assurance. Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, "Chad's appointment further strengthens our executive leadership team and deepens our capabilities as we build the pla

      1/18/22 8:00:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Financials

    Live finance-specific insights

    See more
    • NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

      Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025. Recent Company Highlights Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablati

      5/13/25 7:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time

      EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company's second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the f

      5/1/25 9:55:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

      Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2024. First Quarter Financial Highlights Product revenue increased 235% to $3.3 million in the first quarter of fiscal year 2025, compared to $1.0 million in the first quarter of fiscal

      2/12/25 8:00:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mcclurg Ronald W. bought $100,000 worth of shares (200,000 units at $0.50), increasing direct ownership by 82% to 444,117 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      4/7/25 4:47:21 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • CEO and President Rosa David A bought $50,000 worth of shares (100,000 units at $0.50), increasing direct ownership by 9% to 1,161,289 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      4/7/25 4:38:47 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Volker Christopher bought $105,000 worth of shares (75,000 units at $1.40) (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      12/26/23 4:08:51 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Business Development Director Christianson Mark sold $5,596 worth of shares (8,981 units at $0.62), decreasing direct ownership by 3% to 271,491 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      5/23/25 4:03:34 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Business Development Director Christianson Mark sold $7,306 worth of shares (11,019 units at $0.66), decreasing direct ownership by 4% to 280,472 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      5/21/25 4:14:47 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Business Development Director Christianson Mark

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      4/21/25 5:11:09 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care